Replimune Group Inc.

Candel Therapeutics has secured a much-needed win for its herpes simplex-based immunotherapy, CAN-2409. Phase III results show it helped improve disease-free survival for men with localized prostate c

Private investment in public equity (PIPE) transactions continue to be an important means of fundraising for publicly traded biopharmaceutical companies while the financial markets continue to recover

Checkpoint inhibitors have revolutionized cancer treatment, but they aren’t perfect, and there is a niche for therapies to treat those whose disease progresses despite receiving these therapies. Repl

Special purpose acquisition corporations did not have a very successful run in the last SPAC wave to hit the life science sector, but a new round of the vehicles that provide companies an alternative